AKT1 and cancer: The finding that PI3K/AKT signaling is involved in the response of cancer cells to TTFields prompted us to explore the effects of pharmacological inhibition of this pathway on the responsiveness of cancer cells to TTFields cytotoxicity (Fig. 4A).